Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Endocyte Inc (NASDAQ:ECYT)

2.57
Delayed Data
As of Jan 13
 -0.01 / -0.39%
Today’s Change
2.46
Today|||52-Week Range
4.33
+0.78%
Year-to-Date
Valeant Streamlines Portfolio with Skincare Brands Sale
Jan 11 / Zacks.com - Paid Partner Content
Is Valeant (VRX) Fated for Terrible 2017 As Well?
Jan 03 / Zacks.com - Paid Partner Content
Valeant to Sell Dendreon Unit to Sanpower for $820 Million
Jan 10 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close2.58
Today’s open2.58
Day’s range2.55 - 2.67
Volume114,034
Average volume (3 months)194,192
Market cap$108.6M
Dividend yield--
Data as of 4:00pm ET, 01/13/2017

Growth & Valuation

Earnings growth (last year)-853.85%
Earnings growth (this year)-3.57%
Earnings growth (next 5 years)--
Revenue growth (last year)-99.90%
P/E ratioNM
Price/Sales2,402.53
Price/Book0.63

Competitors

 Today’s
change
Today’s
% change
BDSIBioDelivery Sciences...+0.05+2.56%
PRQRProQR Therapeutics N...+0.25+5.62%
CXRXConcordia Internatio...+0.01+0.46%
ARQLArQule Inc+0.09+6.04%
Data as of 4:00pm ET, 01/13/2017

Financials

Next reporting dateFebruary 27, 2017
EPS forecast (this quarter)-$0.26
Annual revenue (last year)$70.0K
Annual profit (last year)-$41.3M
Net profit margin-58,956.78%

Profile

Sector
Health Technology
Industry
Biotechnology
President, CEO, CFO &
Director
Michael A. Sherman
Director &
Chief Science Officer
Philip S. Low
Corporate headquarters
West Lafayette, Indiana

Forecasts


Search for Jobs